Advertisement
Innocoll's CollaRx technology platform is a biocompatible and fullybioresorbable collagen matrix for localized drug delivery. It is comprised ofpurified type I fibrillar collagen and can be prepared in the form of alyophilized sponge or film-cast membrane using a proprietary manufacturingprocess. Both CollaRx formats can be surgically implanted or applied topicallyto wounds, enabling drugs to be delivered locally to the intended site ofaction and thereby minimize any systemic-related side effects.
Advertisement
CollaRx matrices are biodegraded by natural enzymatic activity and fullyresorbed within a few days or up to several weeks according to the localphysiological environment. The in vivo release of drug from the CollaRx matrixtakes place via a combination of diffusion and natural breakdown of thecollagen to provide both rapid and prolonged release, which can be controlledthrough formulation techniques and processing variables. The CollaRx matrixalso provides an initial scaffold for cell migration and proliferation,thereby stimulating production of certain cytokines and growth factors and soitself plays an integral role in the repair and replacement of both hard andsoft tissue by accelerating tissue granulation and epithelialization.
TGR-265 is a naturally derived bioactive protein that has been shownthrough extensive in vitro and in vivo pre-clinical testing to stimulate thefibrogenic response, production of host type 1 collagen and deposition ofextracellular matrix.
Under the terms of the collaboration, Innocoll will incorporate TGR-265into the CollaRx sponge and membrane formats for further evaluation. TGRBioSciences will fund development of the formulated products.
Commenting on the agreement, Joan FitzPatrick, Executive VP Research &Development of Innocoll Technologies, said, "We are excited to be working withTGR BioSciences on development of this novel product concept combining boththe wound healing properties of native collagen and TGR-265. We believe thereis potential for their mechanisms of action to be both complementary andsynergistic, which could then create a highly potent, elegant, and cost-effective wound healing product."
Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, "Thisstrategic collaboration is indicative of Innocoll's intention to fully exploitits technology platforms through partnership with innovative biotechnology andpharmaceutical companies looking to deliver their drugs locally. Despiteinvesting heavily in the late stage clinical development of our own internalpipeline of products, we believe that partnerships such as this with TGRBioSciences are important for providing the Company with a wide anddiversified portfolio of development projects for long term, sustainablegrowth."
About CollaRx(R)
CollaRx is Innocoll's lead technology platform for the site specific,local delivery of a wide variety of drugs with particular emphasis onantibiotics, anesthetics, anti-cancer agents and tissue regeneration proteinsand peptides. The CollaRx technology forms the basis of Innocoll's leadproduct, Gentamicin Surgical Implant, a biodegradable leave-behind implantindicated for the treatment and prevention of surgical site infection in bothhard and soft tissue. This product is already approved in 49 countries inEurope, Latin America, Middle East, Africa and Asia and is marketed under thefollowing trade names: COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT,GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R),GARACOL(R), GARACOLL(
